Rob Etherington, Clene CEO
Startup's gold nanocrystal ALS drug flops a PhII trial, a reminder of the disease's obstacles despite Amylyx OK
Despite the FDA approving an ALS drug for the first time in five years last week, the disease continues to fluster researchers, and another biotech …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
